Evoke Pharma's 8-K Filing: Key Updates for Investors on February 20, 2025

Based on the provided section of the financial report, here are the key insights extracted:

1. Company Information:

• Name: Evoke Pharma, Inc.
• State of Incorporation: Delaware (DE)
• CIK Number: 0001403708
• Address: 420 Stevens Avenue, Suite 230, Solana Beach, CA 92075
• Phone Number: 858-345-1494

2. Filing Details:

• Filing Type: Form 8-K
• Filing Date: February 20, 2025

3. Stock Information:

• Common Stock: Par value of $0.0001 per share
• Ticker Symbol: EVOK
• Exchange: NASDAQ

4. Context and Period:

• The report is for a specific date, February 20, 2025, indicating it may contain information about an event occurring on that date.

5. Namespace and Schema Reference:

• The document is structured using XBRL (eXtensible Business Reporting Language), which is a standard for digital financial reporting.
• The schema reference indicates that this filing conforms to a specific XBRL schema identified by evok-20250220.xsd.

Summary Insights:

• This filing is a Form 8-K, typically used to report major events that shareholders should know about.
• Evoke Pharma operates under the ticker symbol EVOK on NASDAQ and is incorporated in Delaware.
• The report is dated for a specific event occurring on February 20, 2025, which may indicate a significant development for the company on that date.

Further analysis would require more detailed content from the Form 8-K to understand the specific events or information being reported.